PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40640198,Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza vaccine with bacterial cell membrane-derived adjuvants.,2025,"Kirill Vasilev, Irene Hoxie, Eduard Puente-Massaguer, Joshua Yueh, Disha Bhavsar, Maya Singh, Corey P Mallett, Joseph Zimmermann, Florian Krammer","Inspirevax Inc., Kirkland, Quebec, Canada.; GSK, Rockville, MD, USA.",florian.krammer@mssm.edu
40639387,"Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial.",2025,"Spyros Chalkias, Patrick Dennis, Dena Petersen, Krishnakumar Radhakrishnan, Leroy Vaughan, Reem Handforth, Alexandra Rossi, Rahnuma Wahid, Darin K Edwards, Jing Feng, Weiping Deng, Honghong Zhou, Elizabeth De Windt, Veronica Urdaneta, Yamuna Paila, Bethany Girard, Saul N Faust, Stephen R Walsh, Catherine A Cosgrove, Jacqueline Miller, Rituparna Das","Moderna, Cambridge, MA, USA.; Moderna, Cambridge, MA, USA. Electronic address: Spyros.Chalkias@Modernatx.com.",Spyros.Chalkias@Modernatx.com
